These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8915882)

  • 1. Antibody responses to hepatitis C envelope proteins in patients with acute or chronic hepatitis C.
    Fournillier-Jacob A; Lunel F; Cahour A; Cresta P; Frangeul L; Perrin M; Girard M; Wychowski C
    J Med Virol; 1996 Oct; 50(2):159-67. PubMed ID: 8915882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees.
    Bassett SE; Thomas DL; Brasky KM; Lanford RE
    J Virol; 1999 Feb; 73(2):1118-26. PubMed ID: 9882313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
    Zampino R; Marrone A; Durante Mangoni E; Santarpia L; Sica A; Tripodi MF; Utili R; Ruggiero G; Adinolfi LE
    J Med Virol; 2004 May; 73(1):33-7. PubMed ID: 15042645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of hepatitis C virus envelope proteins expressed in E. coli and insect cells for use as tools for antibody screening.
    Hüssy P; Faust H; Wagner JC; Schmid G; Mous J; Jacobsen H
    J Hepatol; 1997 Jun; 26(6):1179-86. PubMed ID: 9210602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers.
    Depraetere S; Van Kerschaever E; Van Vlierberghe H; Elewaut A; Brouwer JT; Niesters HG; Schalm SW; Maertens G; Leroux-Roels G
    J Med Virol; 2000 Feb; 60(2):126-32. PubMed ID: 10596010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
    Rosa D; Campagnoli S; Moretto C; Guenzi E; Cousens L; Chin M; Dong C; Weiner AJ; Lau JY; Choo QL; Chien D; Pileri P; Houghton M; Abrignani S
    Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1759-63. PubMed ID: 8700831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
    Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
    J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.
    Ali A; Nisar M; Idrees M; Rafique S; Iqbal M
    Int J Infect Dis; 2015 May; 34():84-9. PubMed ID: 25796431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon.
    Frangeul L; Cresta P; Perrin M; Duverlie G; Khorsi H; Musset L; Opolon P; Huraux JM; Lunel F
    J Hepatol; 1998 Apr; 28(4):538-43. PubMed ID: 9566820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
    Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
    J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of antibody to hepatitis C virus E2 recombinant antigen among samples indeterminate for anti-HCV after wide serological testing and correlation with viremia. The Spanish Study Group for Blood Donors at Risk of Transmission of HCV.
    León P; López JA; Elola C; Domingo CJ; Echevarria JM
    Vox Sang; 1996; 70(4):213-6. PubMed ID: 9123926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.
    Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ
    Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of anti-envelope antibodies and clearance of hepatitis C virus in a cohort of Irish women infected in 1977.
    Grellier L; Brown D; Power J; Dusheiko G
    J Viral Hepat; 1997; 4(6):379-81. PubMed ID: 9430357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.
    Liu J; Zhu L; Zhang X; Lu M; Kong Y; Wang Y; Li G
    Biotechnol Appl Biochem; 2001 Oct; 34(2):109-19. PubMed ID: 11592917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
    Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
    J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.